scholarly journals FP372PCSK9 AND INDICES OF CARDIOVASCULAR MORBIDITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE

2019 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Evangelia Dounousi ◽  
Sarantis Papanikolaou ◽  
Kostas Tellis ◽  
Anila Duni ◽  
Paraskevi Pavlakou ◽  
...  
2015 ◽  
Vol 27 (2) ◽  
pp. 75 ◽  
Author(s):  
Alma Muslimovic ◽  
Denijal Tulumovic ◽  
Senad Hasanspahic ◽  
Aida HamzicMehmedbasic ◽  
Ramajana Temimovic

Author(s):  
Ana Ferreira ◽  
◽  
Aníbal Ferreira ◽  
◽  
◽  
...  

Chronic kidney disease – mineral and bone disorders (CKD -MBD) tends to improve or to change phenotypically in the post -transplant period. Mineral and bone disorders post -transplantation (MBD -PT) seem to be associated with high fracture risk and cardiovascular morbidity, and so it is necessary to be aware of its presence to minimize the MBD -PT impact. In this article we summarize the features of MBD -PT.


PRILOZI ◽  
2017 ◽  
Vol 38 (2) ◽  
pp. 19-27
Author(s):  
Aikaterini Papagianni

Abstract Fibroblast Growth Factor (FGF)-23 increase is considered one of the earliest biochemical abnormalities in chronic kidney disease-mineral bone disorder (CKD–MBD). Furthermore, accumulating data have provided evidence of a link between increased FGF-23 levels and cardiovascular morbidity and mortality in CKD patients as well as in several other populations including cardiology patients and general population. The cellular and molecular mechanisms underlying the deleterious effect of FGF-23 on the cardiovascular system are not yet completely defined and are the focus of intense research. However, animal and human studies have demonstrated important actions of FGF-23 in the heart and vessels through which could promote the development of cardiovascular complications in uremia. Moreover, significant interactions have been reported between FGF-23 and other well recognized cardiovascular risk factors such as renin-angiotensin system and inflammation which could account, at least in part, for the observed associations between FGF-23 and adverse clinical outcomes. Further studies are needed to clarify the mechanisms responsible for the pleiotropic actions of FGF-23 and moreover to identify whether it is a modifiable risk factor and a potential target of therapeutic interventions which could probably help to reduce the unacceptably high cardiovascular morbidity and mortality of CKD patients.


2019 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Bojan Stopic ◽  
Brkic Branislava Medic ◽  
Vujovic Katarina Savic ◽  
Zeljko Davidovic ◽  
Marko Stojanovic ◽  
...  

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Chia-Ter Chao ◽  
Szu-Ying Lee ◽  
Jui Wang ◽  
Kuo-Liong Chien ◽  
Kuan-Yu Hung

Abstract Background Chronic kidney disease (CKD) introduces an increased cardiovascular risk among patients with diabetes mellitus (DM). The risk and tempo of cardiovascular diseases may differ depending upon their type. Whether CKD differentially influences the risk of developing each cardiovascular morbidity in patients with newly diagnosed DM remains unexplored. Methods We identified patients with incident DM from the Longitudinal Cohort of Diabetes Patients (LCDP) cohort (n = 429,616), and uncovered those developing CKD after DM and their propensity score-matched counterparts without. After follow-up, we examined the cardiovascular morbidity-free rates of patients with and without CKD after DM, followed by Cox proportional hazard regression analyses. We further evaluated the cumulative risk of developing each outcome consecutively during the study period. Results From LCDP, we identified 55,961 diabetic patients with CKD and matched controls without CKD. After 4.2 years, patients with incident DM and CKD afterward had a significantly higher risk of mortality (hazard ratio [HR] 1.1, 95% confidence interval [CI] 1.06–1.14), heart failure (HF) (HR 1.282, 95% CI 1.19–1.38), acute myocardial infarction (AMI) (HR 1.16, 95% CI 1.04–1.3), and peripheral vascular disease (PVD) (HR 1.277, 95% CI 1.08–1.52) compared to those without CKD. The CKD-associated risk of mortality, HF and AMI became significant soon after DM occurred and remained significant throughout follow-up, while the risk of PVD conferred by CKD did not emerge until 4 years later. The CKD-associated risk of ischemic, hemorrhagic stroke and atrial fibrillation remained insignificant. Conclusions The cardiovascular risk profile among incident DM patients differs depending on disease type. These findings can facilitate the selection of an optimal strategy for early cardiovascular care for newly diagnosed diabetic patients.


Sign in / Sign up

Export Citation Format

Share Document